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2112studies comparing outcomes af-
ter PCI with DES suggest than
DM is no longer a correlate of
restenosis (7,8), whereas others
still identify DM as a predictor
of TLR and TVR (9). Whether
the efﬁcacy of DES in elimi-
nating diabetes as a risk factor
for restenosis depends on lesion
complexity is unknown. In this
regard, lesions in patients with
DM are known to be longer and
present in smaller vessels than in
patients without DM (10). It is
thus conceivable that DM is a
risk factor for restenosis given the
propensity for more complex le-
sions in this condition and that
DM might not predict adverse
outcomes after controlling for
lesion complexity. We therefore
analyzed the efﬁcacy and safety
of DES from a large patient-levelpooled database of 18,471 patients from 18 prospective
randomized trials and examined the impact of DM on pa-
tient outcomes as a function of baseline lesion complexity.
Methods
To perform a comprehensive, patient-level pooled analysis,
we combined 18 databases maintained at the Cardiovascular
Research Foundation from prospective, randomized trials in
which 1-year follow-up of patients treated with DES was
available. The designs of these speciﬁc trials have been pre-
viously described and are summarized in Table 1 (3–5,11–25).
One-year follow-up was completed in all trials, comprising
the follow-up period for this study. The TAXUS, SIRIUS
(Sirolimus-Eluting Stent in De Novo Native Coronary Le-
sions), and ENDEAVOR series of trials evaluated the use
of ﬁrst-generation paclitaxel-eluting, sirolimus-eluting, and
zotarolimus-eluting stents, respectively, compared with BMS
or other DES, whereas the SPIRIT (Clinical Evaluation of
the Xience V Everolimus Eluting Coronary Stent System
in the Treatment of Patients With De Novo Native Cor-
onary Artery Lesions) series of trials and COMPARE
(Comparison of the Everolimus Eluting XIENCE-V Stent
With the Paclitaxel Eluting TAXUS LIBERTÉ Stent in
All-Comers: A Randomized Open Label Trial) compared a
second-generation everolimus-eluting stent with the ﬁrst-
generation paclitaxel-eluting stent. The ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy)
trial compared 3 different pharmacological treatments in
patients with moderate-risk and high-risk acute coronary
syndromes who underwent invasive treatment. Stent
choice (BMS or ﬁrst-generation DES) was at the discre-
tion of the operator. In the HORIZONS-AMI(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial, patients pre-
senting with ST-segment elevation were randomized to PCI
with the ﬁrst-generation paclitaxel-eluting stent versus an
otherwise identical BMS stent.
Endpoints and statistical methods. Because the purpose
of this study was to analyze DES outcomes in patients
with versus without DM, only DES-treated patients were
included in this analysis. Efﬁcacy endpoints were rates of
TLR and TVR. We also examined the rates of TVR-non-
TLR (i.e., TVR remote from the target lesion). Safety
endpoints were all-cause death, cardiac death, myocardial
infarction (MI), deﬁnite and probable stent thrombosis (as
deﬁned by the Academic Research Consortium) (26), and
composite cardiac death or MI. Major adverse cardiac events
(MACE) were deﬁned as the composite of all-cause death,
MI, or TVR. TLR was deﬁned as any repeat revasculariza-
tion procedure (percutaneous or surgical) of the original
target lesion site, including the stent and 5-mm proximal and
distal margins. TVR was deﬁned as any revascularization
procedure occurring within the major epicardial vessel in
which the stent was implanted or its branches. TVR-non-
TLR was deﬁned as any TVR occurring outside the TLR
segment, as described earlier. Events as adjudicated in each
trial were used for the pooled analysis. All analyses are by
intention to treat.
Outcomes of all patients treated with DES were evaluated
according to the presence of medically treated DM. To eval-
uate the impact of baseline lesion severity on efﬁcacy and safety
endpoints, patients with American College of Cardiology
(ACC) andAmericanHeart Association (AHA) classiﬁcation
A/B1 lesions versus those with any B2/C lesions were
compared in theDMandnon-DMcohorts (27). Patientswith
multiple PCI lesionswere included in theB2/Cgroup if at least
1 lesion was B2 or C in complexity; otherwise, they were
included in the A/B1 group. To minimize differences in
baseline characteristics of patients with and those without
DM, 2 equal-sized propensity score–matched groups were
created on the basis of the following variables: sex, hyperten-
sion, hyperlipidemia, previous MI, previous PCI, clinical
syndrome at presentation, and stent type. The C-statistic for
this model was 0.64. Stepwise Cox proportional-hazards
multivariate analysis was performed to further correct for
baseline differences that remained despite the propensity
matching, adjusting for baseline Thrombolysis in Myocardial
Infarction ﬂow and baseline reference vessel diameter. In-
teractions betweenDMandACC/AHA lesion type on 1-year
major safety and efﬁcacy outcomes were examined.
Categorical outcomes were compared using chi-square
tests. Continuous variables are presented as mean  SD
and were compared using Student t tests. Cumulative event
rates were estimated using time-to-event methods and were
compared using the log-rank test. A p value <0.05 was
considered statistically signiﬁcant. All analyses were per-
formed in SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
Table 1 Description of the Prospective Randomized Pooled Trials
Trial (Ref. #) Comparison Randomization Powered for Primary Endpoint
ACUITY (11) 3 drug arms 1:1:1 Noninferiority and superiority Death, MI, unplanned ischemic revascularization
COMPARE (12) EES vs. PES 1:1 Superiority Death, MI, TVR at 1 yr
C-SIRIUS (13) SES vs. BMS 1:1 Superiority In-stent MLD at 8 months
ENDEAVOR II (14) PC-ZES vs. BMS 1:1 Superiority TVF at 9 months
ENDEAVOR III (15) PC-ZES vs. SES 1:3 Noninferiority Late luminal loss at 8 months
ENDEAVOR IV (16) PC-ZES vs. PES 1:1 Noninferiority TVF at 9 months
E-SIRIUS (17) SES vs. BMS 1:1 Superiority In-stent MLD at 8 months
HORIZONS-AMI (18) PES vs. BMS 3:1 Superiority and noninferiority TLR at 12 months; death, MI, stroke, or ST
RAVEL (3) SES vs. BMS 1:1 Superiority In-stent late luminal loss at 6 months
SIRIUS (4) SES vs. BMS 1:1 Superiority TVF at 9 months
SPIRIT II (19) EES vs. PES 3:1 Noninferiority In-stent late loss at 6 months
SPIRIT III (20) EES vs. PES 2:1 Noninferiority or superiority In-segment late loss at 9 months
SPIRIT IV (21) EES vs. PES 2:1 Noninferiority or superiority TLF at 1 yr
TAXUS I (22) PES vs. BMS 1:1 d Death, MI, TVR, ST at 12 months
TAXUS II (23) PES vs. BMS 1:1 Superiority Neointimal proliferation by IVUS at 6 months
TAXUS IV (4) PES vs. BMS 1:1 Superiority Ischemia-driven TVR at 9 months
TAXUS V (24) PES vs. BMS 1:1 Superiority Ischemia-driven TVR at 9 months
TAXUS VI (25) PES vs. BMS 1:1 Superiority Ischemia-driven TVR at 9 months
All trials except COMPARE were multicenter.
ACUITY ¼ Acute Catheterization and Urgent Intervention Triage Strategy; BMS ¼ bare-metal stents; COMPARE ¼ Comparison of the Everolimus Eluting XIENCE-V Stent With the Paclitaxel Eluting TAXUS
LIBERTÉ Stent in All-Comers: A Randomized Open Label Trial; C-SIRIUS ¼ Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients With Long De Novo Lesions in Small Native Coronary
Arteries; DES ¼ drug-eluting stent; EES ¼ everolimus-eluting stent; ENDEAVOR ¼ Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease;
HORIZONS-AMI ¼ Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction; IVUS ¼ intravascular ultrasound; MI ¼ myocardial infarction; MLD ¼ minimal luminal diameter;
PC-ZES ¼ phosphorylcholine polymer-based zotarolimus-eluting stent; PES ¼ paclitaxel-eluting stents; RAVEL ¼ Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the
Treatment of Patients with de Novo Native Coronary Artery Lesions; SES ¼ sirolimus-eluting stents; SIRIUS ¼ Sirolimus-Eluting Stent in De Novo Native Coronary Lesions; SPIRIT ¼ Clinical Evaluation of the
Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions; ST ¼ stent thrombosis; TAXUS ¼ Treatment of De Novo Coronary Disease Using
a Single Paclitaxel-Eluting Stent; TLF ¼ target lesion failure (deﬁned as cardiac death, target vessel MI, or ischemia-driven TLR); TLR ¼ target lesion revascularization; TVF ¼ target vessel failure (deﬁned as
cardiac death, target vessel MI, or TVR); TVR ¼ target vessel revascularization.
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Baseline characteristics. Of 32,644 patients enrolled in the
18 randomized trials, 18,475 were treated with DES. Among
these patients, DM status was known for 18,441 patients
(99.8%), of whom 3,467 (18.8%) had medically treated DM.
Matches were found for 3,167 patients with DM, and thus a
total of 6,334 patients constituted the analysis population.
The baseline clinical angiographic and procedural character-
istics for these patients are shown in Tables 2 and 3. The
majority of patients (64.1%) were men, and the mean age
was 63 years. The proportion of lesions deﬁned by the
ACC/AHA classiﬁcation was similar between the DM and
non-DM groups, although diabetic vessels were slightly
smaller. Lesion severity and length were well matched be-
tween the 2 groups, however, as were procedural outcomes.
Clinical outcomes. As shown in Table 4, there were no
signiﬁcant differences in any endpoint according to diabetic
status at 30 days. At 1 year, TVR rates were signiﬁcantly
increased in patients with DM, because of higher rates of
both TLR and TVR-non-TLR. Similarly, the 1-year rates
of mortality (both cardiac and noncardiac) and stent
thrombosis (both deﬁnite and probable) were signiﬁcantly
higher in patients with DM, with a trend toward more
MI. On multivariate analysis, DM was an independent
predictor of TLR (hazard ratio [HR]: 1.34; 95% conﬁdence
interval [CI]: 1.05 to 1.70; p ¼ 0.02), TVR (HR: 1.40;
95% CI: 1.15 to 1.72; p ¼ 0.001), cardiac death or MI(HR: 1.40; 95% CI: 1.09 to 1.81; p ¼ 0.01), and MACE
(HR: 1.40; 95% CI: 1.19 to 1.65; p < 0.0001). In a
propensity-adjusted multivariate analysis, there were no dif-
ferences in the 1-year rates of death, MI, TLR, TVR, stent
thrombosis, and composite MACE between patients with
DM treated with versus without insulin (data not shown).
Outcomes according to ACC/AHA lesion subtype. As
shown in Figure 1, TLR and TVR rates were increased in
type B2/C compared with A/B1 lesions in the DM cohort
but not in the non-DM cohort. A signiﬁcant interaction was
found between DM and ACC/AHA lesion type for
the 1-year rates of TLR (pinteraction ¼ 0.01) and TVR
(pinteraction ¼ 0.02). Conversely, the rates of cardiac death or
MI and MACE were consistently higher in patients with
compared with those without DM, with no interactions
present between DM and ACC/AHA lesion class for either
endpoint (pinteraction ¼ 0.28 for both). The overall safety
and efﬁcacy interactions between DM status and ACC/
AHA lesion complexity were consistent when lesion types
A, B1, B2, and C were analyzed separately (data not shown).Discussion
The present study, the largest to date examining DES
outcomes according to the presence of DM, demonstrates
that DM remains an independent predictor of clinical
restenosis (i.e., both TLR and TVR), as well as adverse
Table 2 Baseline Clinical, Angiographic, and Stent Characteristics
Variable
DM
(n ¼ 3,167)
No DM
(n ¼ 3,167) p Value
Age (yrs) 63.1  10.6 63.2  10.8 0.83
Men 2,013 (63.6%) 2,047 (64.6%) 0.37
Insulin treatment 880 (27.8%) 0 (0.0%) <0.0001
Smoking (current) 688/2,872 (24.0%) 848/2,879 (29.5%) <0.0001
Hypertension 2,620 (82.7%) 2,626 (82.9%) 0.84
Hyperlipidemia 2,479 (78.3%) 2,492 (78.7%) 0.69
Prior MI 786 (24.8%) 780 (24.6%) 0.86
Prior PCI 851 (26.9%) 856 (27.0%) 0.89
Prior CABG 382/3,166 (12.1%) 284/3,166 (9.0%) <0.0001
ACC/AHA lesion type, worst
Type A 182/3,084 (5.9%) 196/3,083 (6.4%) 0.46
Type B1 830/3,084 (26.9%) 799/3,083 (25.9%) 0.37
Type B2 936/3,084 (30.4%) 949/3,083 (30.8%) 0.71
Type C 1,136/3,084 (36.8%) 1,139/3,083 (36.9%) 0.93
Pre procedural TIMI ﬂow grade, worst vessel
0/1 346/3,091 (11.2%) 372/3,092 (12.0%) 0.30
2 236/3,091 (7.6%) 278/3,092 (9.0%) 0.05
3 2,620/3,091 (84.8%) 2,558/3,092 (82.7%) 0.03
Treated lesions 1.32  0.59 1.28  0.60 0.02
Treated vessels 1.16  0.39 1.15  0.38 0.31
Total number of stents 1.44  0.80 1.42  0.79 0.53
Values are mean  SD or n (%).
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; CABG ¼ coronary artery bypass grafting; DM ¼ diabetes mellitus;
PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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2114safety events, including cardiac death or MI, in the
DES era. However, a strong interaction was present
such that rates of TLR and TVR were increased in patients
with versus those without DM with complex lesionsTable 3 Lesion Characteristics Before and After
Variable
DM
(n ¼ 3,731)
Pre-procedural
Reference vessel diameter (mm) 2.70  0.50
MLD (mm) 0.74  0.43
Diameter stenosis (%) 72.4  14.5
Lesion length (mm) 15.4  8.1
TIMI ﬂow grade
0/1 374/3,724 (10
2 270/3,724 (7.3
3 3,080/3,724 (82
Moderate or severe calciﬁcation 1,056/3,702 (28
Moderate or severe tortuosity 118/1,926 (6.1
Baseline total occlusions 278/2,209 (12
Post-procedural (ﬁnal)
TIMI ﬂow grade
0/1 13/2,895 (0.4
2 80/2,895 (2.8
3 2,802/2,895 (96
Reference vessel diameter (mm) 2.75  0.50
MLD (mm) 0.74  0.43
Diameter stenosis (%) 72.36  14.4
Values are mean  SD, n/total n affected (%), or n (%).
Abbreviations as in Tables 1 and 2.(ACC/AHA class B2/C), but not in patients with more
simple lesions (A/B1). No interaction was present between
lesion complexity and the presence of diabetes on safety
outcomes, although patients with DM had higher rates ofIntervention
No DM
(n ¼ 3,653) p Value
2.74  0.49 0.002
0.75  0.45 0.40
72.4  15.1 0.98
15.3  8.1 0.59
.0%) 399/3,621 (11.0%) 0.17
%) 296/3,621 (8.2%) 0.14
.7%) 2,926/3,621 (80.8%) 0.03
.5%) 985/3,600 (27.4%) 0.27
%) 155/2,019 (7.7%) 0.06
.6%) 299/2,307 (13.0%) 0.71
%) 17/2,741 (0.6%) 0.38
%) 78/2,741 (2.8%) 0.85
.8%) 2,646/2,741 (96.5%) 0.60
2.82  0.51 <0.0001
0.75  0.45 0.40
8 72.37  15.12 0.98
Table 4 Clinical Outcomes at 30 Days and 1 Year According to Diabetic Status
Outcome
DM
(n ¼ 3,167)
No DM
(n ¼ 3,167) HR (95% CI) p Value
30-day outcomes
Death 0.7% (22) 0.4% (12) 1.84 (0.91–3.71) 0.08
Cardiac 0.6% (20) 0.3% (10) 2.01 (0.94–4.29) 0.07
Noncardiac 0.1% (2) 0.0% (1) 2.01 (0.18–22.14) 0.56
MI 2.8% (82) 2.4% (75) 1.09 (0.80–1.49) 0.58
ST
Deﬁnite 0.5% (17) 0.4% (12) 1.42 (0.68–2.98) 0.35
Probable 0.3% (9) 0.1% (3) 3.01 (0.82–11.13) 0.08
Deﬁnite or probable 0.8% (26) 0.5% (15) 1.74 (0.92–3.28) 0.08
TVR 1.2% (38) 1.2% (30) 1.27 (0.79–2.05) 0.33
TLR 1.0% (31) 1.0% (23) 1.35 (0.79–2.31) 0.28
TVR-non-TLR 0.2% (7) 0.2% (7) 1.00 (0.35–2.86) 1.00
Cardiac death or MI 3.4% (101) 2.6% (82) 1.23 (0.92–1.65) 0.16
MACE 4.0% (119) 3.4% (99) 1.20 (0.92–1.57) 0.18
1-yr outcomes
Death 2.6% (79) 1.4% (42) 1.91 (1.32–2.78) 0.0005
Cardiac 1.5% (47) 0.8% (25) 1.91 (1.17–3.10) 0.008
Noncardiac 1.0% (29) 0.5% (16) 1.85 (1.01–3.41) 0.04
MI 4.1% (126) 3.2% (100) 1.27 (0.98–1.65) 0.07
Any ST
Deﬁnite 1.0% (30) 0.5% (17) 1.79 (0.99–3.24) 0.05
Probable 0.4% (12) 0.1% (4) 3.03 (0.98–9.39) 0.04
Deﬁnite or probable 1.4% (42) 0.7% (21) 2.02 (1.20.3.42) 0.007
TVR 9.4% (284) 6.2% (191) 1.54 (1.28–1.85) <0.0001
TLR 6.8% (205) 4.6% (141) 1.50 (1.21–1.86) 0.0002
TVR-non-TLR 2.6% (79) 1.6% (50) 1.62 (1.14–2.31) 0.007
Cardiac death or MI 5.3% (164) 3.8% (120) 1.38 (1.09–1.75) 0.007
MACE 13.9% (429) 9.4% (294) 1.50 (1.29–1.74) <0.0001
Events are % (n) determined using the Kaplan-Meier method.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular events (death, MI, or TVR). Other abbreviations as
in Tables 1 and 2.
JACC Vol. 63, No. 20, 2014 Kedhi et al.
May 27, 2014:2111–8 DES in Patients With and Without Diabetes
2115cardiac death, MI, and stent thrombosis than those with-
out DM.
Our analysis, with 6,334 propensity-matched patients,
was adequately powered to study the impact of DM after
DES treatment for both safety and efﬁcacy endpoints.
Although it is well accepted that DM is a risk factor for
adverse outcomes after PCI, in the present analysis, the
presence of complex lesions, in both patients with and
without DM, was also shown to predict death or MI.
Moreover, the relative rates of TLR and TVR after DES
according to DM status have been uncertain, with prior
studies reporting conﬂicting results (7–9). The present large-
scale study, representing a patient population with a broad
spectrum of clinical presentations varying from stable angina
pectoris to ST-segment elevation MI, demonstrates that
DM is a strong predictor of TLR and TVR with DES.
However, this ﬁnding was conﬁned to patients with complex
lesions (ACC/AHA type B2/C), in whom DM was asso-
ciated with an approximate 80% increase in TLR and TVR
at 1 year compared with those without DM. By contrast, the
1-year rates of TLR and TVR in patients with and without
DM and more simple lesions (ACC/AHA type A/B1)
were excellent (about 95% freedom from revascularization at1 year) and nearly identical. This interaction between dia-
betes and lesion complexity on efﬁcacy outcomes after DES
might also in part explain the disparate ﬁndings in the
previous studies (7–9).
A notable ﬁnding of the present study was the signiﬁ-
cantly higher 1-year TVR-non-TLR rates observed in pa-
tients with versus those without DM. This ﬁnding suggests
that lesion progression may occur more rapidly in patients
with DM, although the absence of routine follow-up angi-
ography in the present study precludes knowing this deﬁn-
itively. Alternatively, it is also possible that patients
with DM had more diffuse disease at baseline (with less
complete initial revascularization), requiring additional PCI
procedures within the ﬁrst year. More rapid lesion pro-
gression and/or lower rates of complete revascularization at
the time of the index procedure may in part contribute to the
superior outcomes of coronary artery bypass grafting
(CABG) compared with PCI in patients with DM, as
recently reported from the FREEDOM (Future Revascu-
larization Evaluation in Patients With Diabetes Mellitus:
Optimal Management of Multivessel Disease) trial (28). In
the PROSPECT (Providing Regional Observations to
Study Predictors of Events in the Coronary Tree) study,
Figure 1 Time-to-Event Curves According to the Presence or Absence of DM and Type A/B1 or Type B2/C Lesion
(A) Target lesion revascularization (TLR); (B) target vessel revascularization (TVR); (C) cardiac death or myocardial infarction (MI); and (D) death, MI, or TVR.
CI ¼ conﬁdence interval; DM ¼ diabetes mellitus; HR ¼ hazard ratio.
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2116DM (particularly insulin-treated DM) was a strong pre-
dictor of unanticipated adverse events originating from un-
treated angiographically mild nonculprit lesions (29).
Conversely, incomplete revascularization is frequent after
PCI and has been strongly linked to subsequent death, MI,
and TVR (30,31). It remains speculative whether more
complete revascularization (perhaps guided with fractional
ﬂow reserve to target ischemic lesions) (32) could thus
improve outcomes in patients with DM.
In contrast to the ﬁndings regarding repeat revascular-
ization, no signiﬁcant relationship was present between
the presence of diabetes, lesion type, and cardiac death or
MI. Of note, the rate of cardiac death or MI was higher
in both patients with DM and those without DM with
type B2/C lesions. Thus, enhanced secondary prevention
therapies are necessary to further reduce rates of death and
MI after DES implantation in both patients with and
without DM.Differences in atherosclerotic plaque composition in
patients with versus those without DM have been reported.
Marso et al. (33) reported from PROSPECT that the
extent of untreated atherosclerosis, calciﬁcation, and the
amount of necrotic core (as assessed by radiofrequency
intravascular ultrasound) were greater in patients with
either DM or metabolic syndrome than in those without
DM, ﬁndings that were associated with a higher 3-year rate
of MACE. Similarly, Zheng et al. (34) showed that the
atherosclerotic plaques in patients with DM or metabolic
syndrome compared with patients without DM had larger
necrotic cores and plaque burden and a higher percentage
of thin-cap ﬁbroatheromas, features that have been strongly
related to plaque rupture (35). These reports have been
recently veriﬁed using optical coherence tomography
(36). Whether such angiographically mild lesions beneﬁt
by treatment with either PCI or CABG, however, is
unknown.
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2117The ﬁndings of the present study demonstrate favorable
intermediate-term results in patients with DM after treat-
ment of noncomplex lesions with DES. Unfortunately, pa-
tients with DM often present with advanced coronary artery
disease and left ventricular dysfunction, due in part to
impaired sensory perception of ischemia. Because the global
incidence of DM is increasing, randomized trials focusing
on the early detection and treatment of atherosclerotic cor-
onary disease in patients with DM might be warranted to
determine whether earlier revascularization with DES or
CABG, coupled with improved systemic therapies, might
improve prognosis in DM.
Study limitations. Because they derive from a post-hoc
patient-level pooled analysis from 18 randomized trials, the
present results should be considered hypothesis generating.
Although the majority of patients were enrolled in trials
without angiographic follow-up, in some of the older trials,
this was not the case, and an effect of the “oculostenotic
reﬂex” (which might be exaggerated in patients with DM)
cannot completely be excluded. Moreover, minor interstudy
variations in MI deﬁnition may have reduced the precision
of this endpoint. The present study was not powered to
examine the impact different types of ﬁrst-generation and/or
second-generation DES might have had on the interaction
between DM status and lesion complexity (although stent
type was used as a variable for the propensity score match to
minimize the impact of any such effects). In this regard,
although a network meta-analysis of randomized trials
suggested that everolimus-eluting stents might be the safest
and most efﬁcacious in patients with DM (37), a recent
nationwide study did not show substantial differences in
clinical restenosis rates between different stent types in pa-
tients with DM (38). Propensity matching might have
resulted in a non-DM cohort with a more severe risk-factor
proﬁle at baseline than the general non-DM population,
which in turn might have muted the differences between
groups. However, our intention was to study the impact of
DM independent of other related risk factors. Baseline renal
insufﬁciency was not uniformly reported, and therefore, this
variable could not be incorporated into the propensity score
matching. Perhaps most important, follow-up was truncated
at 1 year, and thus whether these results apply to longer
durations of follow-up after PCI is not known.
Conclusions
The present analysis, representing the largest study to date
examining DES outcomes in patients with and without
DM, demonstrates that DM remains an independent pre-
dictor of adverse safety and efﬁcacy outcomes in the DES
era. However, freedom from repeat revascularization 1 year
after DES is comparable in patients with and those without
DM with simple lesions treated with DES, whereas patients
with DM with complex lesions have signiﬁcantly higher
rates of repeat revascularization after DES than those
without DM. These data suggest that PCI might havefavorable results compared with CABG if the extent of
disease is not great, consistent with the results from the
SYNTAX (Synergy Between PCI With TAXUS and Car-
diac Surgery) trial (39). However, rates of cardiac death and
MI are increased in patients with DM compared with those
without DM, independent of lesion complexity, empha-
sizing the need for earlier detection and more effective sys-
temic therapies in patients with this high-risk condition.
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